EWING, N.J., March 16 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company) announced today that it has appointed Gregg Lapointe, CPA, MBA, to its Board of Directors. Mr. Lapointe is currently Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company dedicated to the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is DOR's North American partner for orBec(R) and its largest shareholder.
Mr. Lapointe has served in various roles for Sigma-Tau since 2001, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer since April 2008. Prior to Sigma-Tau, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both medical products distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. He received his BA in Commerce from Concordia University in Montreal, Canada, a graduate diploma in accountancy from McGill University and his MBA from Duke University. He is also a CPA in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe also serves on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA) and is a member of the Corporate Council of the National Organization for Rare Diseases (NORD).
'We are very pleased to welcome Gregg Lapointe to our Board of Directors,' said Christopher J. Schaber, PhD, President and CEO of DOR. 'Mr. Lapointe brings extensive experience in the areas of global strategic planning and implementation, corporate finance, accounting, and acquisitions. With his strong business and healthcare background, he is well positioned to make significant contributions to the continued growth and success of DOR. We are enthusiastically looking forward to his productive involvement on our Board.'
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation.
